Keros Therapeutics Collaborates with Bristol Myers Squibb
Ticker: KROS · Form: 8-K · Filed: Jun 4, 2024 · CIK: 1664710
| Field | Detail |
|---|---|
| Company | Keros Therapeutics, Inc. (KROS) |
| Form Type | 8-K |
| Filed Date | Jun 4, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: collaboration, clinical-trial, oncology
Related Tickers: BMY
TL;DR
Keros teams up with BMS for a new cancer drug combo trial starting H2 2024.
AI Summary
Keros Therapeutics, Inc. announced on June 4, 2024, that it has entered into a clinical trial collaboration with Bristol Myers Squibb. This collaboration will evaluate the combination of Keros' investigational drug, elenavex, with Bristol Myers Squibb's Opdualag (nivolumab and relatlimab-rmbw) in patients with advanced solid tumors. The companies will share costs for the trial, which is expected to begin in the second half of 2024.
Why It Matters
This collaboration could lead to a new combination therapy for advanced solid tumors, potentially improving treatment outcomes for patients and expanding the market for Keros' drug candidate.
Risk Assessment
Risk Level: medium — Clinical trial collaborations carry inherent risks related to drug efficacy, patient recruitment, and regulatory approval, which can impact the company's future prospects.
Key Players & Entities
- Keros Therapeutics, Inc. (company) — Registrant
- Bristol Myers Squibb (company) — Collaboration Partner
- elenavex (drug) — Keros' investigational drug
- Opdualag (nivolumab and relatlimab-rmbw) (drug) — Bristol Myers Squibb's drug
- June 4, 2024 (date) — Date of Report
- second half of 2024 (date) — Expected trial start
FAQ
What is the primary purpose of the collaboration between Keros Therapeutics and Bristol Myers Squibb?
The collaboration aims to evaluate the combination of Keros' investigational drug, elenavex, with Bristol Myers Squibb's Opdualag in patients with advanced solid tumors.
When is the clinical trial expected to commence?
The clinical trial is expected to begin in the second half of 2024.
Which investigational drug is Keros Therapeutics contributing to the collaboration?
Keros Therapeutics is contributing its investigational drug, elenavex.
Which drug is Bristol Myers Squibb contributing to the collaboration?
Bristol Myers Squibb is contributing its drug, Opdualag (nivolumab and relatlimab-rmbw).
What is the target patient population for this clinical trial?
The target patient population for this clinical trial is patients with advanced solid tumors.
Filing Stats: 529 words · 2 min read · ~2 pages · Grade level 9.9 · Accepted 2024-06-04 08:01:31
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 par value per share KROS The Nasdaq Sto
Filing Documents
- kros-20240604.htm (8-K) — 36KB
- exhibit9916424pr.htm (EX-99.1) — 9KB
- 0001664710-24-000050.txt ( ) — 173KB
- kros-20240604.xsd (EX-101.SCH) — 2KB
- kros-20240604_lab.xml (EX-101.LAB) — 22KB
- kros-20240604_pre.xml (EX-101.PRE) — 13KB
- kros-20240604_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On June 4, 2024, Keros Therapeutics, Inc. (the "Company") issued a press release announcing that the Company will host a corporate update conference call and webcast on Monday, June 17, 2024 at 8:00 a.m. Eastern time. The Company also announced that it received positive feedback from the U.S. Food and Drug Administration regarding the KER-050 (elritercept) myelodysplastic syndromes ("MDS") program, which resulted in general alignment on the design and endpoints for the proposed pivotal Phase 3 clinical trial in patients with MDS. The Company also announced that it expects to complete enrollment of its ongoing Phase 2 clinical trial evaluating KER-012 (cibotercept) in patients with pulmonary arterial hypertension in the fourth quarter of 2024. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release dated June 4, 2024. 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KEROS THERAPEUTICS, INC. By: /s/ Jasbir Seehra Jasbir Seehra, Ph.D. Chief Executive Officer Dated: June 4, 2024